The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin

@article{PinkasKramarski1998TheOE,
  title={The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin},
  author={Ronit Pinkas-Kramarski and Anne E. G. Lenferink and Sarah S. Bacus and Ljuba Lyass and Monique van de Poll and Leah N. Klapper and Eldad Tzahar and Michael N. Sela and E.J.J. van Zoelen and Yosef Yarden},
  journal={Oncogene},
  year={1998},
  volume={16},
  pages={1249-1258}
}
The ErbB-1 receptor tyrosine kinase binds to six different growth factors, whose prototype is the epidermal growth factor (EGF). Two homologous epithelial receptors, ErbB-3 and ErbB-4, bind all isoforms of another family of growth factors, the Neu differentiation factors (NDFs/neuregulins). The fourth member of the ErbB family, ErbB-2, acts as the preferred heterodimeric partner of ligand-occupied complexes of the three other ErbB proteins. Here we report that at high concentrations, EGF can… 
Biochemistry of HER2 oncogenesis in breast cancer.
TLDR
It is concluded that ErbB-2 developed as a master regulator of a signaling network essential for normal physiology, but opportunistically is exploited by oncogenic mechanisms, and this understanding may prove useful for developing clinical strategies to inhibit Erb B-mediated cancer.
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors.
TLDR
Oncogenicity of ErbB-2 in human epithelia may not rely on the existence of a specific ligand but rather on its ability to act as a coreceptor for multiple stroma-derived growth factors.
ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network
TLDR
It is concluded that the NRG-ErbB network represents a complex and nonredundant machinery developed for fine-tuning of signal transduction.
The EGFR/ERBB Receptor Family
TLDR
The ability of ERBB/HER proteins to redirect signals by means of network plasticity is emerging as an important way developed by tumors to evade pharmacological interceptors aimed at specific nodes of the network.
The ERBB3 receptor in cancer and cancer gene therapy
TLDR
A wide and centrally important role for ERBB3 in cancer is becoming increasingly apparent and small inhibitory RNA to ERBB2 or AKT is showing promise as a therapeutic approach to treatment of lung adenocarcinoma.
erbB genes in the mouse uterus: cell-specific signaling by epidermal growth factor (EGF) family of growth factors during implantation.
TLDR
Autophosphorylation and immunoprecipitation studies provided evidence that uterine ErbB3 andErbB4 are biologically active and a comprehensive analysis of possible ligand-receptor signaling schemes for EGF-like ligands in implantation.
Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity.
TLDR
Comparison of ErbB species between the tumorigenic cells (E 6T) and their nontumorigenic derivatives (E6TA) demonstrated all four receptors in both cell types, suggesting that ErbbB-1 is a preferred heterodimer partner within this cell system and that their expression levels may be increased by signaling initiated by TGF-alpha.
...
...

References

SHOWING 1-10 OF 12 REFERENCES
Crit
  • Rev. Oncol. Hematol., 19, 183 ± 232.
  • 1995
Mol
  • Cell. Biol., 15, 1182 ± 1191.
  • 1995
Cancer Treat
  • Res., 71, 161 ± 191.
  • 1994
Proc
  • Natl. Acad. Sci. USA, 90, 1746 ± 1750.
  • 1993
The Epidermal Growth Factor Family
TLDR
Histological studies indicated that the precocious eyelid opening in “factor-treated” animals was the consequence of a generalized increase in epidermal thickening and keratinization (Cohen and Elliott 1963).
Mol
  • Cell. Biol., 14, 1909 ± 1919.
  • 1994
Proc
  • Natl. Acad. Sci. USA, 91, 8132 ± 8136.
  • 1994
Biochem
  • Biophys. Acta, 1266, 83 ± 90.
  • 1995
Eur
  • J. Immunol., 18, 97 ± 104.
  • 1988
The epidermal growth factor family (Springer Verlag, New York) pp
  • 69 ± 171.
  • 1991
...
...